The progress of the clinical implication and management of prostate ductal adenocarcinoma
10.3781/j.issn.1000-7431.2024.2306-0321
- VernacularTitle:前列腺导管腺癌诊疗进展
- Author:
Xiaojie BIAN
1
;
Yao ZHU
;
Dingwei YE
Author Information
1. 复旦大学附属肿瘤医院泌尿外科,上海 200232
- Keywords:
Prostate cancer;
Ductal adenocarcinoma;
Diagnosis;
Treatment;
Prognosis
- From:
Tumor
2024;44(1):44-53
- CountryChina
- Language:Chinese
-
Abstract:
Ductal adenocarcinoma(DAC)is the most common histological variant of prostate cancer with an aggressive characteristic.Due to the rarity of the disease,DAC can be difficult to identify by traditional diagnostic modalities such as serum prostate-specific antigen(PSA)and multi-parameter magnetic resonance imaging.Optimal treatment mode for local DAC is still under exploration.After radical prostatectomy or radiotherapy,most DACs are prone to recurrence or metastasis at low PSA levels,and systemic therapy for high-risk prostate cancer is less effective in the treatment of DAC.Current genomic analysis of DAC has provided laboratory evidence for its aggressive behavior and potential therapeutic targets,but the exploration of the mechanism of the biological behavior of DAC still needs to be addressed.
